Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

60.34

+0.18 (0.30%)

as of Jul 21, 2026, 2:49:32 pm Market Open.

160 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Bristol Myers Squibb (BMY-N) presents a mixed outlook among experts. Some highlight its attractive dividend yield, a promising drug pipeline, and the company's reasonable valuation given its wide economic moat. Despite this, there's caution regarding the performance of specific drugs such as Cobenfy, which has recorded disappointing sales. Nonetheless, the company's recent earnings report showed positive momentum, with an EPS of $1.63 surpassing estimates and sales growth of 3%. Management has raised its revenue guidance for 2025, indicating bullish prospects for its growth portfolio, which includes newer and higher-growth drugs. The ongoing challenges faced by the legacy portfolio remain a concern, but the potential for recovery exists if the growth portfolio continues to outpace declines in legacy sales.

Consensus

Mixed

Valuation

Undervalued

Similar

EliLilly, LLY

DON'T BUY

Demographics are good for pharmaceuticals but over the last 16 months, they have been terrible performers. Probably were over owned as defensive stocks. Has a number of drugs coming off patent. Avoiding this sector.

BUY

Large, US pharmaceutical stocks typically do well in a rising interest rate environment. Has suffered a lot of market price weakness recently and is now attractive. Also attractive in their cash flow model. 4 1/2% dividend yield.

TOP PICK

4 1/2 percent yield. Underperform the other big pharma stocks because of accounting issues which they have now got out-of-the-way. A big part of their portfolio will be subject to competition from generic drugs but have a great pipeline of new drugs.

DON'T BUY

Pays over 4% dividends. Has had its share of screw ups over the last couple of years. Doesn't have a lot of faith in the management. Would prefer owning a Pfizer or a European one.

TOP PICK

About 25% below what it's worth. Have a very good record of growing their earnings. Healthy return on equity of 14%.

BUY

Big pharma stocks should do well in this market. Historically, they do well when rates start to move up. Very attractive yield.

DON'T BUY

Big-cap pharmas have been quite a disappointment. Have had some problems with channel stuffing. Looks cheap on an earnings basis but prefers others.

SELL

Continuing to underperform. Dividend yield of over 4%, but feels there's valuation risk.

DON'T BUY

Drug stocks are not acting well. A weak stock in a weak market is not good.

HOLD

Valuation is getting a little high. Their pipeline is still a "show me" story.

DON'T BUY

Pharmaceuticals stocks have recently rallied but probably because of defensive moves rather than growth. A little bit skeptical. Would like to see earnings growth in relation to the valuations.

TOP PICK

Big pharma have been under pressure, but also seeing a really strong trend in biotechs. Has a broad product line. High dividend yield. Decent multiple.

BUY

Looks like momentum is coming back. All drugs look pretty good.

DON'T BUY

Fairly large dividend yield. There has been speculation that the dividend could be trimmed. Not a fan of management. Prefers Pfizer.

WEAK BUY

Their model price is just a couple of dollars over the current price. Prefers Amgen.

Showing 181 to 195 of 221 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Bristol Myers Squibb (BMY)